Table 6. List of Excluded Studies and Reason for Exclusion

Study	Reasons for exclusion*
Abbouda et al, 2017[1]	No available individual-level data
Alabduljalil et al, 2015[2]	Conference abstract
Aleman et al, 2017[3]	RPE area not assessed by FAF
Aleman et al, 2018[4]	Conference abstract
Al-Qahtani et al, 2018[5]	No necessary data
Bains et al, 2003[6]	Conference abstract
Batmanabane et al, 2017[7]	Conference abstract
Birtel et al, 2019[8]	Overlapping dataset
Camino et al, 2018[9]	No necessary data
Chung et al, 2014[10]	Conference abstract
Cideciyan et al, 2015[11]	No necessary data
Colucci et al, 2016[12]	Conference abstract
Coussa et al, 2012[13]	Overlapping dataset
Cunningham et al, 2018[14]	Conference abstract
Di Iorio et al, 2019[15]	No necessary data
Dimopoulos et al, 2015[16]	Conference abstract
Dimopoulos et al, 2016[17]	Overlapping dataset
Dimopoulos et al, 2017[18]	Conference abstract
Duncan et al, 2002[19]	No necessary data
Edwards et al, 2016[20]	Conference abstract
Esposito et al, 2011[21]	Overlapping dataset
Forsius et al, 1977[22]	No necessary data
Freund et al, 2013[23]	Conference abstract
Freund et al, 2016[24]	No necessary data
Fry et al, 2018[25]	Conference abstract
Fujiki et al, 1999[26]	No necessary data
Genead et al, 2011[27]	Overlapping dataset
Genead et al, 2011[28]	Conference abstract
Genead et al, 2011[29]	No necessary data
Gocho et al, 2017[30]	Conference abstract
Groppe et al, 2013[31]	Conference abstract
Grover et al, 1998[32]	Overlapping dataset
Halioua-Haubold et al, 2019[33]	Overlapping dataset
Han et al, 2017[34]	Overlapping dataset
Han et al, 2018[35]	Overlapping dataset
Han et al, 2018[36]	No necessary data
Hariri et al, 2017[37]	No necessary data
Hariri et al, 2018[38]	Conference abstract
Hariri et al, 2019[39]	No necessary data
Hayakawa et al, 1999[40]	No necessary data
Heon et al, 2016[41]	No necessary data
Hirakawa et al, 1999[42]	Less than 5 patients
Jolly et al, 2015[43]	Overlapping dataset
Jolly et al, 2016[44]	Conference abstract
Jolly et al, 2017[45]	No necessary data
Karna et al, 1986[46]	No necessary data
Katz et al, 2006[47]	Less than 5 patients
Khan et al, 2016[48]	No necessary data
Kurstjens et al, 1965[49]	No necessary data
Lam et al, 2017[50]	Conference abstract
Lam et al, 2018[51]	Conference abstract
Lam et al, 2019[52]	No necessary data
Lazow et al, 2011[53]	Conference abstract
Lazow et al, 2011[54]	No necessary data
Li et al, 2014[55]	No necessary data
MacDonald et al, 1996[56]	Conference abstract
MacDonald et al, 2016[57]	Conference abstract

MacLaren et al, 2014[58]	Conference abstract
MacLaren et al, 2014[59]	Overlapping dataset
MacLaren et al, 2016[60]	Conference abstract
MacLaren et al, 2018[61]	Conference abstract
Moosajee et al, 2014[62]	Conference abstract
Morgan et al, 2014[63]	No necessary data
Morgan et al, 2018[64]	Conference abstract
Murro et al, 2019[65]	Overlapping dataset
Mysore et al, 2013[66]	Conference abstract
Patricio et al, 2017[67]	Conference abstract
Pennesi et al, 2018[68]	Conference abstract
Pichi et al, 2013[69]	Overlapping dataset
Prokofyeva et al, 2009[70]	No necessary data
Prokofyeva et al, 2010[71]	Conference abstract
Renner et al, 2006[72]	No necessary data
Roberts et al, 2002[73]	No necessary data
Salvetti et al, 2017[74]	Conference abstract
Sandberg et al, 2006[75]	No necessary data
Seitz et al, 2018[76]	Overlapping dataset
Simunovic et al, 2016[77]	Overlapping dataset
Simunovic et al, 2017[78]	Overlapping dataset
Skorczyk-Werner et al, 2018[79]	No necessary data
Spandau et al, 2002[80]	Less than 5 patients
Sun et al, 2016[81]	No necessary data
Traband et al, 2016[82]	Conference abstract
Tuten et al, 2019[83]	Overlapping dataset
van Schuppen et al, 2018[84]	No necessary data
Wang et al, 2018[85]	No necessary data
Wilson et al, 2018[86]	Conference abstract
Xue et al, 2016[87]	Overlapping dataset
Xue et al, 2016[88]	Conference abstract
Yeoh et al, 2010[89]	Less than 5 patients
Zeitz et al, 2016[90]	Conference abstract
Zhao et al, 2002[91]	Conference abstract
Zinkernagel et al, 2013[92]	Less than 5 patients

FAF = fundus autofluorescence; RPE = retinal pigment epithelium.

* “No necessary data” represents studies did not report necessary data for the present meta-analysis, including the area of residual retinal pigment epithelium measured by fundus autofluorescence, and the ages of individual patients.

References:

1. Abbouda A, Lim WS, Sprogyte L, et al. Quantitative and qualitative features of spectral-domain optical coherence tomography provide prognostic indicators for visual acuity in patients with choroideremia. Ophthalmic Surg Lasers Imaging Retina 2017;48(9):711-6.
2. Alabduljalil T, Araya MPP, Trang H, et al. Phenotypic characteristics and natural history of choroideremia. 2015;56 (7):3838.
3. Aleman TS, Han G, Serrano LW, et al. Natural history of the central structural abnormalities in choroideremia: A prospective cross-sectional study. Ophthalmology 2017;124(3):359-73.
4. Aleman TS, Silson EH, Willett A, et al. Fmri derived visual field measures correlate highly with clinical perimetry assessments in choroideremia patients. Mol Ther 2018;26(5):415-.
5. Al-Qahtani AA, Ba-Ali S, Alabduljalil T, et al. Scleral pits in choroideremia: Implications for retinal gene therapy. Retina 2018;38(9):1725-30.
6. Bains HS, Jampol LM. Characterization of posterior pole chorioretinal features using optical coherence tomography in patients with diffuse and focal chorioretinal atrophy. Invest Ophthalmol Vis Sci 2003;44:U680-U.

7. Batmanabane V, Vincent A, Heon E. Retinal sensitivity and fixation stability as surrogate markers of visual function in molecularly confirmed choroideremia patients. Invest Ophthalmol Vis Sci 2017;58(8).
8. Birtel J, Salvetti AP, Jolly JK, et al. Near-infrared autofluorescence in choroideremia: Anatomic and functional correlations. Am J Ophthalmol 2019;199:19-27.
9. Camino A, Wang Z, Wang J, et al. Deep learning for the segmentation of preserved photoreceptors on en face optical coherence tomography in two inherited retinal diseases. Biomed Opt Express 2018;9(7):3092-105.
10. Chung DC, Morgan JIW, Charlson ES, et al. Structural findings in carriers and affected individuals with choroideremia - an optical coherence tomography study. Invest Ophthalmol Vis Sci 2014;55(13):3383.
11. Cideciyan AV, Swider M, Jacobson SG. Autofluorescence imaging with near-infrared excitation:Normalization by reflectance to reduce signal from choroidal fluorophores. Invest Ophthalmol Vis Sci 2015;56(5):3393-406.
12. Colucci R, Boccia R, Di Iorio V, et al. Clinical presentation and disease course in choroideremia patients. Invest Ophthalmol Vis Sci 2016;57(12):159.
13. Coussa RG, Kim J, Traboulsi EI. Choroideremia: Effect of age on visual acuity in patients and female carriers. Ophthalmic Genet 2012;33(2):66-73.
14. Cunningham C, Daggett H, Stone E, Han I. Scleral pits are a sign of disease severity in choroideremia. Invest Ophthalmol Vis Sci 2018;59(9):6059.
15. Di Iorio V, Esposito G, De Falco F, et al. Chm/rep1 transcript expression and loss of visual function in patients affected by choroideremia. Invest Ophthalmol Vis Sci 2019;60(5):1547-55.
16. Dimopoulos I, MacDonald IM. Mesopic and scotopic threshold sensitivity in patients with choroideremia: Relationship with residual fundus autofluorescence area. Invest Ophthalmol Vis Sci 2015;56(7):2223.
17. Dimopoulos IS, Tseng C, MacDonald IM. Microperimetry as an outcome measure in choroideremia trials: Reproducibility and beyond. Invest Ophthalmol Vis Sci 2016;57(10):4151-61.
18. Dimopoulos IS, Knowles J, Sajed T, MacDonald IM. Fundus autofluorescence analysis of the transition zone in choroideremia: Outcomes following gene therapy. Invest Ophthalmol Vis Sci 2017;58(8).
19. Duncan JL, Aleman TS, Gardner LM, et al. Macular pigment and lutein supplementation in choroideremia. Exp Eye Res 2002;74(3):371-81.
20. Edwards T, Jolly J, Groppe M, et al. 2. Sustained improvement in visual acuity after retinal gene therapy for choroideremia. 2016;44 (Supplement 1):22.
21. Esposito G, De Falco F, Tinto N, et al. Comprehensive mutation analysis (20 families) of the choroideremia gene reveals a missense variant that prevents the binding of rep1 with rab geranylgeranyl transferase. Hum Mutat 2011;32(12):1460-9.
22. Forsius H, Hyvarinen L, Nieminen H, Flower R. Fluorescein and indocyanine green fluorescence angiography in study of affected males and in female carriers with choroidermia. A preliminary report. Acta Ophthalmol (Copenh) 1977;55(3):459-70.
23. Freund P, Furgoch M, MacDonald I. Genotype-phenotype analysis of male subjects affected by choroideremia. Invest Ophthalmol Vis Sci 2013;54(15):1567.
24. Freund PR, Sergeev YV, MacDonald IM. Analysis of a large choroideremia dataset does not suggest a preference for inclusion of certain genotypes in future trials of gene therapy. Mol Genet Genomic Med 2016;4(3):344-58.
25. Fry L, Patricio MI, Williams J, et al. Pathological donor splice site mutations beyond the dinucleotide canonical sequence in choroideremia. 2018;59(9):3493.
26. Fujiki K, Hotta Y, Hayakawa M, et al. Rep-1 gene mutations in japanese patients with choroideremia. Graefes Arch Clin Exp Ophthalmol 1999;237(9):735-40.
27. Genead MA, McAnany JJ, Fishman GA. Retinal nerve fiber thickness measurements in choroideremia patients with spectral-domain optical coherence tomography. Ophthalmic Genet 2011;32(2):101-6.
28. Genead MA, Fishman GA. Presence and treatment of cystoid macular edema in patients with choroideremia. 2011;2011:2130.
29. Genead MA, Fishman GA. Cystic macular oedema on spectral-domain optical coherence tomography in choroideremia patients without cystic changes on fundus examination. 2011;25(1):84-90.
30. Gocho K, Akeo K, Kubota D, et al. High resolution imaging analysis of female carriers and patients of choroideremia with chm gene mutation. Invest Ophthalmol Vis Sci 2017;58(8).
31. Groppe M, Cottriall C, Downes S, MacLaren R. Correlation of retinal sensitivity with the area of normal auto-fluorescence in choroideremia patients. Invest Ophthalmol Vis Sci 2013;54(15):642.

32. Grover S, Alexander KR, Choi DM, Fishman GA. Intraocular light scatter in patients with choroideremia. Ophthalmology 1998;105(9):1641-5.
33. Halioua-Haubold CL, Jolly JK, Smith JA, et al. Potential lifetime quality of life benefits of choroideremia gene therapy: Projections from a clinically informed decision model. Eye (Lond) 2019.
34. Han RC, Jolly JK, Xue K, MacLaren RE. Effects of pupil dilation on maia microperimetry. Clin Exp Ophthalmol 2017;45(5):489-95.
35. Han RC, Gray JM, Han J, et al. Optimisation of dark adaptation time required for mesopic microperimetry. Br J Ophthalmol 2018;29:29.
36. Han X, Li H, Wu S, et al. Study of natural history of chinese patients with choroideremia. [chinese]. 2018;36(7):519-25.
37. Hariri AH, Velaga SB, Girach A, et al. Measurement and reproducibility of preserved ellipsoid zone area and preserved retinal pigment epithelium area in eyes with choroideremia. Am J Ophthalmol 2017;179:110-7.
38. Hariri AH, Girach A, Ip MS, et al. Spatial distribution of preserved autofluorescence in patients with choroideremia. 2018;59(9):4991.
39. Hariri AH, Ip MS, Girach A, et al. Macular spatial distribution of preserved autofluorescence in patients with choroideremia. Br J Ophthalmol 2019;103(7):933-7.
40. Hayakawa M, Fujiki K, Hotta Y, et al. Visual impairment and rep-1 gene mutations in japanese choroideremia patients. Ophthalmic Genet 1999;20(2):107-15.
41. Heon E, Alabduljalil T, McGuigan ID, et al. Visual function and central retinal structure in choroideremia. Invest Ophthalmol Vis Sci 2016;57(9):OCT377-87.
42. Hirakawa H, Iijima H, Gohdo T, et al. Progression of defects in the central 10-degree visual field of patients with retinitis pigmentosa and choroideremia. Am J Ophthalmol 1999;127(4):436-42.
43. Jolly JK, Groppe M, Birks J, et al. Functional defects in color vision in patients with choroideremia. Am J Ophthalmol 2015;160(4):822-31 e3.
44. Jolly JK, Cottriall CL, Groppe M, MacLaren RE. Characterisation of scotopic vision in patients with choroideremia utilising full-field stimulus threshold (fst). Invest Ophthalmol Vis Sci 2016;57(12):621.
45. Jolly JK, Xue K, Edwards TL, et al. Characterizing the natural history of visual function in choroideremia using microperimetry and multimodal retinal imaging. Invest Ophthalmol Vis Sci 2017;58(12):5575-83.
46. Karna J. Choroideremia. A clinical and genetic study of 84 finnish patients and 126 female carriers. Acta Ophthalmol Suppl 1986;176:1-68.
47. Katz BJ, Yang Z, Payne M, et al. Fundus appearance of choroideremia using optical coherence tomograpy. Adv Exp Med Biol 2006;572:57-61.
48. Khan KN, Islam F, Moore AT, Michaelides M. Clinical and genetic features of choroideremia in childhood. Ophthalmology 2016;123(10):2158-65.
49. Kurstjens JH. Choroideremia and gyrate atrophy of the choroid and retina. Doc Ophthalmol 1965;19(1):2-122.
50. Lam BL, Verriotto J, Gregori N, Davis JL. Choroideremia gene therapy phase ii clinical trial: 6-month results. Invest Ophthalmol Vis Sci 2017;58(8).
51. Lam BL, Fischer MD, Pennesi ME, et al. Natural history of progression of choroideremia (night) study: Cross-sectional analysis of baseline characteristics. 2018;59(9):3899.
52. Lam BL, Davis JL, Gregori NZ, et al. Choroideremia gene therapy phase 2 clinical trial: 24-month results. 2019;197:65-73.
53. Lazow MA, Hood DC, Birch DG. Fdoct analysis of the transition zone between healthy and severely affected regions in patients with choroideremia. 2011;2011:4976.
54. Lazow MA, Hood DC, Ramachandran R, et al. Transition zones between healthy and diseased retina in choroideremia (chm) and stargardt disease (stgd) as compared to retinitis pigmentosa (rp). Invest Ophthalmol Vis Sci 2011;52(13):9581-90.
55. Li S, Guan L, Fang S, et al. Exome sequencing reveals chm mutations in six families with atypical choroideremia initially diagnosed as retinitis pigmentosa. 2014;34(2):573-7.
56. MacDonald IM, Chen M, Mitchell G, et al. Mutation analysis of canadian families with choroideremia. Invest Ophthalmol Vis Sci 1996;37(3):5237-.
57. MacDonald IM, Dimopoulos I, Chan S, et al. Ocular gene therapy for choroideremia: The alberta experience. Invest Ophthalmol Vis Sci 2016;57(12).

58. MacLaren RE, Groppe M, Barnard AR, et al. Improved visual function in patients with choroideremia undergoing subretinal gene therapy. 2014;55 (13):832.
59. MacLaren RE, Groppe M, Barnard AR, et al. Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. Lancet 2014;383(9923):1129-37.
60. MacLaren RE, Edwards TL, Jolly J, et al. Long term vision results following retinal gene therapy for choroideremia. 2016;57(12).
61. MacLaren RE, Xue KM, Barnard AR, et al. Retinal gene therapy for choroideremia in a multicenter dose escalation phase i/ii clinical trial. Invest Ophthalmol Vis Sci 2018;59(9).
62. Moosajee M, Ramsden SC, Black GC, et al. Spectrum of chm mutations, structural retinal features and their progression in choroideremia patients within the uk. Invest Ophthalmol Vis Sci 2014;55(13):2136.
63. Morgan JI, Han G, Klinman E, et al. High-resolution adaptive optics retinal imaging of cellular structure in choroideremia. Invest Ophthalmol Vis Sci 2014;55(10):6381-97.
64. Morgan JIW, Tuten WS, Cooper RF, et al. Cellular-scale assessment of visual function in choroideremia. Invest Ophthalmol Vis Sci 2018;59(9):1151.
65. Murro V, Mucciolo DP, Giorgio D, et al. Optical coherence tomography angiography (oct-a) in young choroideremia (chm) patients. 2019;40(3):201-6.
66. Mysore N, Cao S, Koenekoop J, et al. Choroideremia is a systemic disease with retinal crystals, lymphocyte crystals and serum lipid abnormalities. 2013;54(15):716.
67. Patricio MI, Barnard AR, Orlans HO, et al. Inclusion of the woodchuck hepatitis virus posttranscriptional regulatory element enhances aav2-driven transduction of mouse and human retina. Mol Ther Nucleic Acids 2017;6:198-208.
68. Pennesi ME, Lam BL, Fischer MD, et al. The natural history of the progression of choroideremia (night) study: Longitudinal changes in visual acuity over 12 months. 2018;59(9):3898.
69. Pichi F, Morara M, Veronese C, et al. Multimodal imaging in hereditary retinal diseases. J Ophthalmol 2013;2013:634351.
70. Prokofyeva E, Wilke R, Lotz G, et al. An epidemiological approach for the estimation of disease onset in central europe in central and peripheral monogenic retinal dystrophies. Graefes Arch Clin Exp Ophthalmol 2009;247(7):885-94.
71. Prokofyeva E, Troeger E, Wilke R, Zrenner E. Age of visual symptoms onset in different types of inherited retinal degenerations. 2010;51(13):3548.
72. Renner AB, Kellner U, Cropp E, et al. Choroideremia: Variability of clinical and electrophysiological characteristics and first report of a negative electroretinogram. 2006;113(11):2066-73.
73. Roberts MF, Fishman GA, Roberts DK, et al. Retrospective, longitudinal, and cross sectional study of visual acuity impairment in choroideraemia. Br J Ophthalmol 2002;86(6):658-62.
74. Salvetti AP, Birtel J, Xue K, et al. Near-infrared autofluorescence in choroideremia: Anatomical and functional correlations. 2017;58(8).
75. Sandberg MA, Gaudio AR. Reading speed of patients with advanced retinitis pigmentosa or choroideremia. Retina 2006;26(1):80-8.
76. Seitz IP, Jolly JK, Dominik Fischer M, Simunovic MP. Colour discrimination ellipses in choroideremia. Graefes Arch Clin Exp Ophthalmol 2018;256(4):665-73.
77. Simunovic MP, Jolly JK, Xue K, et al. The spectrum of chm gene mutations in choroideremia and their relationship to clinical phenotype. Invest Ophthalmol Vis Sci 2016;57(14):6033-9.
78. Simunovic MP, Xue K, Jolly JK, MacLaren RE. Structural and functional recovery following limited iatrogenic macular detachment for retinal gene therapy. JAMA Ophthalmol 2017;135(3):234-41.
79. Skorczyk-Werner A, Wawrocka A, Kochalska N, Krawczynski MR. Novel chm mutations in polish patients with choroideremia - an orphan disease with close perspective of treatment. Orphanet J Rare Dis 2018;13(1):221.
80. Spandau UH, Wechsler S, Blankenagel A. Testing night vision goggles in a dark outside environment. Optom Vis Sci 2002;79(1):39-45.
81. Sun LW, Johnson RD, Williams V, et al. Multimodal imaging of photoreceptor structure in choroideremia. PLoS One 2016;11(12):e0167526.
82. Traband A, Fuerst N, Serrano L, et al. Natural history of the central structural abnormalities in choroideremia: Insights from a cross-sectional study. 2016;57(12):6587.
83. Tuten WS, Vergilio GK, Young GJ, et al. Visual function at the atrophic border in choroideremia assessed with adaptive optics microperimetry. 2019;08:08.

84. van Schuppen SM, Talib M, Bergen AA, et al. Long-term follow-up of patients with choroideremia with scleral pits and tunnels as a novel observation. Retina 2018;38(9):1713-24.
85. Wang Z, Camino A, Hagag AM, et al. Automated detection of preserved photoreceptor on optical coherence tomography in choroideremia based on machine learning. J Biophotonics 2018;11(5):e201700313.
86. Wilson IR, Jolly J, Downes S, MacLaren RE. Beyond the average threshold: Alternatives in the analysis of microperimetry data. 2018;59(9):1698.
87. Xue K, Oldani M, Jolly JK, et al. Correlation of optical coherence tomography and autofluorescence in the outer retina and choroid of patients with choroideremia. Invest Ophthalmol Vis Sci 2016;57(8):3674-84.
88. Xue K, Oldani M, Jolly J, et al. Rpe degeneration precedes photoreceptor and choroidal loss in choroideremia based on enhanced-depth oct and fundus autofluorescence correlations. 2016;57(12).
89. Yeoh J, Rahman W, Chen F, et al. Choroidal imaging in inherited retinal disease using the technique of enhanced depth imaging optical coherence tomography. 2010;248(12):1719-28.
90. Zeitz C, Kloeckener-Gruissem B, Lancelot M-E, et al. A comprehensive molecular analysis of patients with the diagnosis of choroideremia. 2016;57(12):661.
91. Zhao D, Wintch SW, Gellermann W, Bernstein PS. Resonance raman spectroscopic measurement of macular carotenoid pigments in patients with choroidal and retinal dystrophies. 2002;2002:2544.
92. Zinkernagel MS, Groppe M, MacLaren RE. Macular hole surgery in patients with end-stage choroideremia. Ophthalmology 2013;120(8):1592-6.